Novavax to Move Forward With Covid-19-Flu Vaccine

FDA lifts pause on Novavax flu vaccine trials
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated to the combination shot,
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
FDA Lifts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Up
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax shares were up more than 13 percent in pre-market.
FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Novavax, Inc.: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today
Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot
The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ:MNDY).
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.
Zacks.com on MSN4h
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
FiercePharma5d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Novavax, UK terminate vaccine supply agreement
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...
bovnews3d
Novavax Inc (NVAX) Stock Sees Market Value Hit $1.47 billion: What Are the Implications?
On Thursday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.18 which represents a slight increase of $0.22 or 2.46% from the prior close of $8.96. The stock opened at $9.16 and ...
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average Target Price from Analysts
Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to ...